Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bull 2X Shares ETF
ERX
VanEck Semiconductor ETF
SMH
4
The Technology Select Sector SPDR® Fund
XLK
5
Invesco Solar ETF
TAN
CN Stock MarketDetailed Quotes
BeOne Medicines Ltd. (688235)
- 239.97
- +0.77+0.32%
Market Closed May 19 15:00 CST
369.89BMarket Cap116.94P/E (TTM)
242.46High235.58Low3.04MlotVolume238.59Open239.20Prev Close726.92MTurnover2.65%Turnover Ratio253.13P/E (Static)1.54BShares346.0052wk High11.20P/B27.61BFloat Cap213.3352wk Low287.04Limit Up115.06MShs Float346.00Historical High191.36Limit Down2.88%Range %82.00Historical Low--Dividend TTM238.83Avg Price1.52MlotAsk--Div Yield TTM1Lot Size1.37MlotBid
688235 Stock Chart
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
688235 Orderflow
Unit: --
688235 Orderflow Trend
IntradayDayWeekMonth
No Data
BeOne Medicines Ltd. (688235) News
Here's How Much $100 Invested In BeOne Medicines 10 Years Ago Would Be Worth Today
Major banks are collectively bullish on BeiGene (06160), with Q1 results confirming its long-term investment value.
Quarterly revenue surpassed RMB 10 billion, and net profit surged more than 178-fold year over year... Driven by the robust realization of its innovative value, BeiGene (688235.SH, 06160, ONC.US) delivered a Q1 2026 financial report that exceeded expectations, validating the company's ability to generate sustainable profitability and sending a further positive allocation signal to global capital markets.
The Demystification Moment in AI-Driven Drug Discovery: From Conceptual Proof‑of‑Concept "Storytelling" to Clinical Validation "Seeing Reality"—New Therapies Are Accelerating Breakthroughs.
① AI-driven drug development is returning to rationality, focusing on 'clinical benefits' to reduce costs and improve efficiency for pharmaceutical companies; however, data silos and the shortage of multidisciplinary talents remain as bottlenecks for implementation. ② Breakthroughs in new therapies are being achieved, with in vivo CAR-T advancing toward outpatient treatment and small nucleic acid drugs opening up the chronic disease market. ③ MNC cooperation strategies are being upgraded, with clinical data reliability, CMC and global filing capabilities, differentiation, and innovative mechanisms becoming key considerations.
BeOne Wins FDA Nod for BEQALZI Lymphoma Therapy
BeOne Medicines Is Maintained at Outperform by Leerink Partners
Express News | Beone Medicines : Leerink Partners Raises Target Price to $367 From $364
BeOne Medicines Ltd. (688235) Stock Forum
Morning Movers
Gapping Up
$Lumentum (LITE.US)$ climbed 4.88% in premarket trading after Nvidia invested 2 billion in Marvell and announced a strategic partnership that boosted sentiment for AI optical interconnect suppliers.
$Newmont (NEM.US)$ climbed 3.93% in premarket trading due to a rebound in gold prices on easing Middle East tensions and remarks from Fed Chair Powell signaling no need for rate hikes.
$Ciena (CIEN.US)$ clim...
Gapping Up
$Lumentum (LITE.US)$ climbed 4.88% in premarket trading after Nvidia invested 2 billion in Marvell and announced a strategic partnership that boosted sentiment for AI optical interconnect suppliers.
$Newmont (NEM.US)$ climbed 3.93% in premarket trading due to a rebound in gold prices on easing Middle East tensions and remarks from Fed Chair Powell signaling no need for rate hikes.
$Ciena (CIEN.US)$ clim...
8
1
Morning Movers
Gapping Up
$Fitness Champs (FCHL.US)$ soared 122.81% in premarket trading after implementing a fifteen for one reverse share split to regain Nasdaq minimum bid compliance.
$EpicQuest Education (EEIQ.US)$ soared 59.33% in premarket trading.
$Olaplex (OLPX.US)$ soared 50.38% in premarket trading after Henkel agreed to acquire Olaplex for 2.06 dollars per share in cash a roughly 55 percent premium to the prior clos...
Gapping Up
$Fitness Champs (FCHL.US)$ soared 122.81% in premarket trading after implementing a fifteen for one reverse share split to regain Nasdaq minimum bid compliance.
$EpicQuest Education (EEIQ.US)$ soared 59.33% in premarket trading.
$Olaplex (OLPX.US)$ soared 50.38% in premarket trading after Henkel agreed to acquire Olaplex for 2.06 dollars per share in cash a roughly 55 percent premium to the prior clos...
8
Below is 2/10 P/L with a ~50/50 holding of $BeiGene (ONC.US)$ and $Tencent Music (TME.US)$.
Just transferred some random stocks in and this is largely the performance of those stocks (two ADRs listed in US exchange). Would love to see how to add some FX and currency element into current portfolio. App looks fun and interesting to use, or just to look at and kill some time. New year strategy is mainly to stay the course and don't trade too much. Depending on the market or policy mov...
Just transferred some random stocks in and this is largely the performance of those stocks (two ADRs listed in US exchange). Would love to see how to add some FX and currency element into current portfolio. App looks fun and interesting to use, or just to look at and kill some time. New year strategy is mainly to stay the course and don't trade too much. Depending on the market or policy mov...
2
Morning Movers
Gapping Up
$Immunome (IMNM.US)$ surged 23.1% in premarket trading after announcing positive Phase 3 results for varegacestat in desmoid tumors including a significant improvement in progression free survival versus placebo and a 56 percent objective response rate.
$Canopy Growth (CGC.US)$ increased 5.17% in premarket trading due to reports that President Trump is expected to sign an executive order reclassifying...
Gapping Up
$Immunome (IMNM.US)$ surged 23.1% in premarket trading after announcing positive Phase 3 results for varegacestat in desmoid tumors including a significant improvement in progression free survival versus placebo and a 56 percent objective response rate.
$Canopy Growth (CGC.US)$ increased 5.17% in premarket trading due to reports that President Trump is expected to sign an executive order reclassifying...
12
3
1
Morning Movers
Gapping Up
$Olema Pharmaceuticals (OLMA.US)$ soared 313.26% in premarket trading after Roche reported that giredestrant met its primary endpoint in a Phase 3 adjuvant trial for ER positive HER2 negative early stage breast cancer raising optimism for Olema palazestrant.
$Can-Fite BioPharma (CANF.US)$ soared 46.1% in premarket trading after announcing ongoing enrollment in a pivotal Phase III trial of Namodenoson for ...
Gapping Up
$Olema Pharmaceuticals (OLMA.US)$ soared 313.26% in premarket trading after Roche reported that giredestrant met its primary endpoint in a Phase 3 adjuvant trial for ER positive HER2 negative early stage breast cancer raising optimism for Olema palazestrant.
$Can-Fite BioPharma (CANF.US)$ soared 46.1% in premarket trading after announcing ongoing enrollment in a pivotal Phase III trial of Namodenoson for ...
8
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)